semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Abdominal Pain • Acute presentation with abdominal pain and/or tenderness which is most marked in the right lower abdomen  Age<18 Age>60 Pregnancy Patients with a firm clinical diagnosis of appendicitis where surgical management is indicated at presentation Patients who have undergone CT scanning within the past two months Patients with cognitive impairment who would lack capacity to give consent Inability to understand written or spoken English Patients who have previously undergone appendicectomy
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Aspiration Pneumonias • Endotracheal intubation and invasive mechanical ventilation  Immediate postoperative oral cavity Traumatic oral cavity injury Platelet count less than 50000
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Clostridium Difficile Clostridium Difficile Infection consecutive patients with documented CDI infection, including with mild-moderate CDI with severe CDI with severe complicated/fulminant CDI, according to definition
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection Age 18 or older Hospitalized patient with documented positive stool test for CDiff Able and willing to provide informed consent  Pregnancy Breastfeeding Known allergy to BSS or other salicylates, including aspirin History of bleeding disorder History of gastrointestinal bleed History of gastrointestinal ulcer Chronic use of anticoagulants Chronic NSAID use
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Antibiotic Resistant Infection Chronic Diarrhea of Unknown Origin Patient hospitalized for an episode of C. difficile colitis Patient hospitalized multidrug resistant bacteria Patient hospitalized for chronic diarrhea without etiologies Patient is more than 18 years old  Minor patient
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diarrhea, Clostridium Difficile Patients hospitalized on antibiotics (single or multiple; oral or IV) assuming that they are able to eat/drink so that they can take the pills Regimen started within 48 hours of first course of antibiotics Able to sign a consent form  diarrhea on admission; bowel pathology that could result in diarrhea (eg. IBD), bowel surgeries and pouches; immunocompromised state (including febrile aplasia, immunosuppressive therapy, ICU patients, HIV-positive patients and renal transplant patients); prosthetic heart valves or history of endocarditis and rheumatic heart disease; use of metronidazole, vancomycin or fidaxomycin prior to stool culture for Clostridium difficile toxins
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection Clostridium Difficile Patients with a confirmed diagnosis of CDI, as documented by diarrheal symptoms and positive stool test result for C. difficile toxin or toxigenic C. difficile, or colonoscopic findings of pseudomembranous colitis (PMC) Patients aged over or equal to 18 years old Patients able and willing to provide informed consent  Patients with concomitant infection by other microbes such as Salmonella, Campylobacter, Vibrio, Shigella, and Escherichia coli Patients under 18 years old Patients who cannot give consent
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Ulcerative Colitis Established diagnosis of UC for 12 months or more Distal disease, accessible by flexible sigmoidoscopy Mild to moderate UC as defined as Mayo score between 3 with Mayo endoscopic sub score ≥1  A known hypersensitivity to any of the inactive ingredients of the study treatment A diagnosis of any IBD except UC Isolated proctitis Stool culture positive for C. difficile or other enteric infection Untreated tuberculosis (TB); positive QuantiFERON-TB Gold Test result (performed by Central Laboratory) Evidence of previous or present hepatitis B or C infection Known severe viral infection within six weeks prior to Visit 1 Current use of topical mesalazine or anti-infectives for serious infection (or within 1 week) Anti-TNFα therapy other than the study drug Parenteral or enteral nutrition therapy
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Clostridium Difficile Infection age 18 or higher documented recurrence of Clostridium difficile  none
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Stroke Diagnosed with AIS, TIA or ICH Admitted to the Department of Neurology at Aarhus University Hospital or Regional Hospital West Jutland (Holstebro) Age ≥ 18 years Onset of symptoms ≤ 7 days before time of interview  Modified Rankin Scale (mRS) ≥ 3* (pre-stroke) Transferred from other regions in Denmark or abroad Not willing to participate in the study Cannot be reached ("out of office") Non-Danish speaking
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Aspiration Pneumonia presence of risk factors for aspiration  known or likely swallowing dysfunction altered consciousness cardiac arrest difficult intubation witnessed aspiration symptoms and signs suggestive of lower respiratory tract pathology temperature ≥38.5°C or <36°C leukocyte count ≥10 000/µL or <1500/µL purulent sputum or tracheal aspirate  pregnant women refuse to participate to the study no informed consent documented bacteremia septic shock severe immunosuppression: leukocytes<1000/L or neutrophils<500/L, chemotherapy during the last 3 months, organ transplant with chronic immunosuppressors use, HIV (CD4<50), and chronic corticosteroid use (>0.5 mg/kg day for at least one month during the last three months) moribund patients (SAPS II >90)
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Multiple Myeloma Diarrhea Memorial Sloan Kettering Cancer Center (MSK) confirmed diagnosis of multiple myeloma Treatment with single agent lenalidomide maintenance Patient must be >/= 18 years of age at the time of informed consent Experiencing grade 1 or more diarrhea according to the CTCAE 5.0 for at least 4 out of 7 days preceding screening and study Scheduled to receive lenalidomide maintenance cyles at MSK Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures  Patients with history of bowel obstruction Patients with serum triglyceride levels >300 mg/dL Patients wit history of hypertriglyceridemia-induced panreatitis Patients with known hypersensitivity to colesevelam or any component to the formulation Patients currently already receiving a bile acid sequestrant or have previously used bile acid sequestrant drugs for diarrhea and had no benefit Patients with diarrhea secondary to infection. Infections will need to be ruled out (Clostridium difficile PCR when clinically indicated, GI pathogen panel, stool ova and parasites, Giardia and Cryptosporum stool antigen tests) prior to starting treatment in all patients
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Muscle Weakness Patients will be recruited in the Intensive Care Unit of the Royal Liverpool University Hospital. All patients will be over 18, and have a critical illness that requires mechanical ventilation with an initial period of sedation. This study will focus on patients with a definite or suspected case of sepsis from any source. Sepsis has been recently redefined as: "Life threatening organ-dysfunction caused by dysregulated host response to infection" whilst septic shock has become a subset of sepsis, defined as: "circulatory and cellular/metabolic dysfunction associated with a higher risk of mortality(44). For the purposes of this study, a patient will be regarded as septic if they have evidence of infection-related organ failure (e.g. sepsis-associated coagulopathy, altered mental state, cardiovascular dysfunction, acute kidney injury, and altered liver function) and require invasive mechanical ventilation with either definite or suspected evidence of infection. This is to allow prompt treatment with FES rather than waiting for a positive microbiological result to be obtained. Within the definition of sepsis "from any source" a list of following is illustrative but not exhaustive Urogenital sepsis (including urosepsis, pyelonephritis, endometritis and chorioamnionitis) Pneumonia (including community acquired, hospital acquired, and aspiration pneumonia. Ventilator associated pneumonia would be excluded.) Neurological infections such as encephalitis and meningitis Cellulitis, osteomyelitis and infections of soft tissue NOT affecting the lower limb Surgical infections, including post-operative laparotomy with evidence of peritoneal soiling, and evidence of infection prior to the operation, in patients who require 2 or more organ system support after the operation Intra-abdominal sepsis, including biliary sepsis, hepatitis, and acute pancreatitis. In the case of acute pancreatitis, evidence of infection is required to fulfil the criteria. Acute pancreatitis with sterile tissue/fluid samples would not be suitable  Patients under 18 Patients who decline consent Pregnancy Neuromuscular disease Rhabdomyolysis Lower limb trauma Patients unlikely to survive to 96 hours post admission Consent unobtainable within 48 hours of admission Morbid obesity (BMI>40) Presence of a pacemaker or Implantable Cardiac Defibrillator (ICD)
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection Recurrence Clostridium Difficile Infection Clostridium Difficile CDI Partial 1. Able and willing to provide written informed consent 2. Subjects with a qualifying CDI episode who have a prior history of CDI diarrhea or first occurrence of CDI diarrhea with a higher risk for recurrence (≥ 65 years of age) 3. CDI symptoms must have started within 30 days (inclusive) prior to the day of randomization 4. The diarrhea is considered unlikely to have another etiology. 5. Complete an Investigator's choice SOC antibiotic regimen of a minimum of 10 days and up to 21 days of total duration 6. Have a positive C. difficile stool 7. Recovered from any complications of severe or fulminant CDI and clinically stable by the time of randomization. Partial  History of diarrhea (defined as 3 or more loose stools per day lasting for at least 4 weeks) that is not related to C. difficile infection within the 3 months prior to randomization. 2. Known or suspected toxic megacolon and/or known small bowel ileus at the time of randomization. 3. Contraindication to oral/enteral therapy (e.g., severe reflux, severe nausea/vomiting, or ileus). 4. Prior administration of genetically modified investigational live bacterial/fungal/bacteriophage/viral isolates for CDI-associated diarrhea 5. History of administration of fecally-derived investigational live biotherapeutic products, or fecally-derived live bacterial isolates for CDI-associated diarrhea including fecal microbiota transplantation (FMT) within the last 6 months. 6. Use of drugs that alter gut motility 7. History of acute leukemia or hematopoietic stem cell transplantation or myelosuppressive chemotherapy within 2 months prior to randomization. 8. Subjects with compromised immune system 9. Major gastrointestinal surgery (e.g., significant bowel resection or diversion) within 3 months prior to randomization or any history of total colectomy or bariatric surgery that disrupts the gastrointestinal lumen. 10. History of confirmed celiac disease, inflammatory bowel disease, short gut, gastrointestinal tract fistulas, or ischemia
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Beta-lactam Antibiotics Therapeutic Drug Monitoring Toxicity Efficacy Imipenem Meropenem Piperacillin Flucloxacillin Amoxicillin Ceftazidime Cefepime Hospitalized patients with suspected or confirmed systemic bacterial infection: 1. Receiving either imipenem-cilastatin, meropenem, amoxicillin (±clavulanic acid), flucloxacillin, piperacillin-tazobactam, ceftazidime or cefepime 2. Aged ≥18 years 3. Requiring intensive or intermediate-intensive (step-down) care OR severely immunosuppressed (see definitions)  Planned imminent transfer to an outside hospital 2. Poor prognosis with life expectancy <1 week and/or intended transition to palliative care
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Diarrhea Enrollment episode of CDAD diagnosed based on > 3 loose stools per day and detection of CD toxin by nucleic acid amplification tests (NAAT), EIA or GDH Mild to moderate CDAD during enrollment episode (per Society of Hospital Epidemiologists of America (SHEA)/lnfectious Disease Society of America(ISDA) criteria) Current therapy with standard of care antibiotics for recurrent CDAD(vancomycin, metronidazole, fidaxomicin) BMI > 18.5 and < 40 Age 18 years or older Agreement to adhere to the study protocol Informed consent is obtained Women who are capable of bearing children must have a negative pregnancy test at the time of screening Female subjects of childbearing potential must use birth control (defined as oral or injectable contraceptives, intrauterine devices, surgical sterilization or a combination of a condom and spermicide) during the study period and for up to 8 weeks after the first drug of study  Severe CDAD during enrollment episode (per SHEA/ISDA criteria) characterized as follows History of five (5) or more recurrences of CDAD within the past 12 months prior to potential study enrollment History of fecal microbiome transplant or other microbiome directed experimental intervention for CDAD History (ever) of CD complicating inflammatory bowel disease (Crohn's disease, ulcerative colitis), or history of bowel resection surgery (other than uncomplicated appendectomy) or history of other infectious diarrhea or diarrhea of unknown etiology since the initial episode of CDAD Clinically immunocompromised due to any primary immune or autoimmune deficiency, as a result of chronic disease, cancer or medication used to treat these diseases Initiating a new diet or weight loss amounting to 10% within two weeks prior to date of study entry Enrolled in another clinical study for the therapy of CDAD or affecting nutritional management during the study period Enrolled or has been enrolled in another experimental (IND) study within two weeks prior to date of study entry Is pregnant or lactating History of swallowing difficulties, including dysphagia or odynophagia for liquids or solids